Abstract Details

Title CD62L (L-selectin) is Not a Reliable Biomarker for Predicting Risk of Progressive Multifocal Leukoencephalopathy in Natalizumab-Treated Multiple Sclerosis Patients

Topic Multiple Sclerosis

Presentation(s) (-)

Poster/Presentation
Number 039

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Linda Lieberman PRESENTER	No disclosure on file
	No disclosure on file
Tatiana Plavina, PhD	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Leonid Gorelik, PhD	No disclosure on file
Ludwig Kappos, MD, FAAN (RC2NB, University Hospital Basel)	Dr. Kappos has nothing to disclose.
	No disclosure on file

��ɫ��

��ɫ��

Abstract Details

��ɫ����

��ɫ����

��ɫ��

��ɫ��